Nevertheless, several blocking antibodies and small molecules for VEGF‐A–VEGFR2 signaling (Hurwitz et al, 2004; Van Cutsem et al, 2012; Wilke et al, 2014) are currently being used for patients with solid cancers such as colorectal cancers. Here, KDR is linked to colorectal cancer.